25 Jun, 2019 · In News
12 Sep, 2019 · In Press Releases
World’s first soft robotic muscle strengthening system. Developed in collaboration with leading Fortune 500 companies
08 Mar, 2019
The Nomination Committee of Bioservo Technolies AB (publ) has decided to propose to the Annual General Meeting the following proposals for the number of Board members and the election of Board members. The Nomination Committee proposes that the number of Board members on the Board should be six (6). The Nomination Committee proposes, for the period until the end of the next Annual General Meeting, re-election of the Board members Anders Lundmark, Runar Bjørklund, Hans von Holst, Karin Ruiz and Kunal Pandit, as well as new elections of Nikolaj Sørensen. As the Chairman of the Board, it is proposed that Anders Lundmark be re-elected. Tomas Ward has declined re-election.
Nikolaj Sørensen is President and CEO of Orexo AB, a publicly Swedish specialty pharmaceutical company with a focus on treatment of opioid dependence and pain. Nikolaj has been CEO of Orexo AB since 2013 and has contributed to the establishment of Orexo in the US and the transformation of Orexo from development companies to a company in a commercial phase. His background with experience of international commercialization and in particular the American market is very relevant to Bioservo when we start the broad commercial launch of Ironhand and Carbonhand. Nikolaj Sørensen is a graduate economist and before Orexo has worked many years in senior positions and as an advisor in life science in Sweden and internationally.
Tomas Ward has been a board member since 2017 and was CEO of Bioservo between 2012 and 2017. He has been important for several of the company's important cooperation agreements and EU projects.
Questions are referred to:
Runar Björklund, Chairman of the Nomination Committee
Brief about Bioservo Technologies
Bioservo Technologies (publ) is a technology and development company that combines medical science with modern robotics. The company holds a leading global position within soft exoskeleton technology – wearable non-invasive devices – for people in need of extra power to optimise the body’s endurance and performance, or for people with reduced muscle strength.
After many years of research and development, Bioservo Technologies is now focused on a commercialisation of the company’s products and patented technologies. The gloves are well-suited to medical rehabilitation, and to preventive use by healthcare professionals. The company has, for example, signed strategic partnership agreements with several multinational companies within the automotive and aerospace industry as well as companies active in construction/ infrastructure.
Bioservo Technologies was founded in 2006 through a collaboration between researchers at the Royal Institute of Technology and doctors at Karolinska University Hospital in Stockholm. Bioservo Technologies is a Swedish public limited company with its headquarters and operations based in Kista, north of Stockholm. FNCA Sweden AB, +46(0)8-52800399, firstname.lastname@example.org is the company’s Certified Adviser on Nasdaq First North.
For more information, please visit www.bioservo.com